214 results
Page 6 of 11
424B2
rlz7e3ns 5c
29 May 14
Prospectus for primary offering
12:00am
8-K
zb991 v6u75y6zq
27 May 14
A Phase 2 Trial of BCX4161 for the Prophylactic Treatment of
12:00am
424B5
2eo6y5y1
27 May 14
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
44335929fyi
27 May 14
A Phase 2 Trial of BCX4161 for the Prophylactic Treatment of
12:00am
8-K
EX-99.1
ab7sjgvbikes9tkr
18 Dec 13
Biocryst Advances Second Generation Oral Plasma Kallikrein Inhibitors for Hereditary Angioedema into Preclinical Development
12:00am
8-K
EX-1.1
x2ml8wxi5pf
5 Aug 13
Biocryst Pharmaceuticals Prices Public Offering of Common Stock
12:00am
424B2
afv4j6rtjne620g
2 Aug 13
Prospectus for primary offering
12:00am
424B5
4bfngrfzbnnpp f7fw
30 Jul 13
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
dzm3 ocat
22 Jul 13
Biocryst Successfully Completes Its Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema
12:00am
8-K
EX-2.1
jhimn
22 Oct 12
Entry into a Material Definitive Agreement
12:00am
425
EX-2.1
rvkrjk0tetr hgynu3
22 Oct 12
Business combination disclosure
12:00am
8-K
EX-10.1
krcytlxda 0mzayjb
25 May 12
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.2
d48i8yuj
25 May 12
Departure of Directors or Certain Officers
12:00am